Phase II Trial of High Dose Intravenous Vitamin C in Patients With Refractory Non-Hodgkin Lymphoma
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
10 weeks
No
Daniel Monti, MD
Principal Investigator
Faculty Member
United States: Food and Drug Administration
IND-77486
NCT00626444
February 2008
December 2011
Name | Location |
---|---|
Jefferson-Myrna Brind Center of Integrative Medicine | Philadelphia, Pennsylvania 19107 |